Botulinum Toxin for the Treatment of Involuntary Movement Disorders

Conditions Phase Intervention Type
N/A
Other
Botulinum Toxin

Eligibility

Ages Eligible for Study
4 years and up
Genders Eligible for Study
Both

Keywords

Spasmodic Torticollis, Writers Cramp, Spasmodic Dysphonia, Stuttering, Oromandibular Dystonia, Palatal Myoclonus, Dystonia, Essential Tremor, and Movement Disorders

Sponsors

NIH
National Institute of Neurological Disorders and Stroke (NINDS)

Inclusion Criteria

Patients will be eligible for participation if they have a disorder that, in the judgment
of the treating physician, might be amenable to treatment with BTX.

Applicable disorders include but are not limited to dystonia, hemifacial spasm,
blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual
dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.

Exclusion Criteria

Patients will be excluded form participation if:

1. They are pregnant or breastfeeding, for the duration of the condition.

2. They require treatment with an aminoglycoside antibiotic, until treatment is
complete.

3. For laryngeal injections, they have a paradoxical vocal fold movement with
intermittent stridor due to either gastroesophageal reflux or emotional disorders.

Detailed Description

Botulism is a severe form of food poisoning caused by bacteria. This bacteria produces several toxins one of which is botulinum toxin A. This toxin causes the symptoms of food poisoning. Small amounts of botulinum toxin A have been used to treat speech disorders such as stuttering and problems with the muscles of the eyes. The study examines the effectiveness of botulinum toxin as treatment for a variety of movement disorders. The goals of the study are to refine the technique of treatment to provide the best results, to improve the understanding of how botulinum toxin works on movement disorders, and find other conditions that may be treatable with botulinum toxin. In addition, researchers also plan to study the possible use of botulinum toxin F alone and in combination with botulinum toxin A in patients who do not respond to botulinum A toxin treatment.<TAB>

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001208

Overall Contact

Mark Hallett, M.D.
(301) 496-9526

Overall Contact Backup

Elaine P Considine, R.N.
(301) 435-8518

Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland United States

    Status: Recruiting

    Contact info For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)
    800-411-1222xTTY8664111010